[P4–552]: AN ANALYTICAL FRAMEWORK TO PROJECT THE POTENTIAL MEDICARE COST BENEFIT OF INTEPIRDINE (RVT101) IN MILD‐MODERATE ALZHEIMER'S DISEASE. (1st July 2017)